Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
The latest update for P3 Health Partners lifts the internal fair value reference from $10.25 to $14.00, signaling a higher price target in current analyst models. That move is tied closely to recent commentary that balances optimism about 2026 execution, cleaner debt and equity structures, and higher EBITDA guidance with caution around how durable the reset in sentiment and valuation may be. As you read on, you will see how this evolving narrative might shape the way you track P3 Health Partners from here.
Stay updated as the Fair Value for P3 Health Partners shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on P3 Health Partners.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
TD Cowen highlighted that P3 Health Partners reported 1Q26 adjusted EBITDA of $26m, which the firm viewed as well ahead of its estimates. TD Cowen cited this as a key factor behind lifting its price target to $14 from $3.
-
TD Cowen also pointed to an increased midpoint of EBITDA guidance to about $30m, aligning P3 Health Partners with a broader group of payers and capitated providers that reported better than expected 1Q26 results.
-
Lake Street raised its price target on P3 Health Partners to $14 from $4 and described 2026 as off to an auspicious start, referencing debt converted to equity and what it views as a shored up balance sheet.
-
Lake Street told investors it sees the possibility for substantial upside and meaningful multiple expansion as more assured today than in prior years, signalling a more constructive view on valuation reset potential.
🐻 Bearish Takeaways
-
While turning more constructive, Lake Street still cautioned that it may take a couple more quarters for sentiment on P3 Health Partners to fully shift. This could limit how quickly valuation re rates in the near term.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 3 risks for P3 Health Partners. See which could impact your investment.
How This Changes the Fair Value For P3 Health Partners
-
Fair value reference updated from US$10.25 to US$14.00 for P3 Health Partners.
-
Revenue growth assumption revised from 11.10% to 6.19%.
-
Net profit margin assumption updated from 5.17% to 6.10%.
-
Future P/E assumption adjusted from 0.43x to 0.55x.
-
Discount rate assumption moved from 12.33% to 12.25%.